<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="47255">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491047</url>
  </required_header>
  <id_info>
    <org_study_id>BonyPid-1000TM-103</org_study_id>
    <nct_id>NCT02491047</nct_id>
  </id_info>
  <brief_title>Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo IIIA and IIIB Tibial Open Fractures</brief_title>
  <official_title>Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo IIIA and IIIB Tibial Open Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PolyPid Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PolyPid Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multi-national, multicenter, randomized, two arms, single blind,
      Standard of Care (SOC) controlled, with blinded central reading center study. This study
      will assess the safety and performance of BonyPid-1000™ in severe open tibial fractures
      (Gustilo IIIA and IIIB) when implanted as adjunct to SOC and compared to SOC alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety: Deep Infection in the target fracture site</measure>
    <time_frame>During the 4 weeks post index procedure</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Performance: Radiographic-assessed bone healing</measure>
    <time_frame>During the 24-week follow-up period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Tibial Fractures</condition>
  <condition>Open Fractures</condition>
  <arm_group>
    <arm_group_label>BonyPid-1000TM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BonyPid-1000™ implantation concomitantly with standard of care treatment (SOC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study control arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care treatment (SOC) only</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BonyPid-1000TM</intervention_name>
    <description>BonyPid-1000TM implantation concomitantly to standard of care (SOC) treatment</description>
    <arm_group_label>BonyPid-1000TM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of Care (SOC) treatment</intervention_name>
    <description>Standard of Care (SOC) treatment only</description>
    <arm_group_label>Study control arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or non-pregnant female with age ≥ 18 years and ≤70 years.

          2. Subjects with tibia open fractures of Gustilo grade, IIIA or IIIB

          3. Multi-injured subjects who are hemodynamically and physiologically stable

          4. Subjects who are able and willing to sign an informed consent form, prior to any
             protocol-specific procedures being performed and accept to comply with protocol
             requirements for the duration of the study.

        Exclusion Criteria:

          1. Female who is pregnant or breastfeeding.

          2. Subjects with known current disseminated malignancies, active cancer or autoimmune
             diseases.

          3. Subjects with fractures due to known medical history of Osteoporosis.

          4. Diabetic subjects who are drug or insulin dependent.

          5. Heavy smokers in the last 6 months.

          6. Non-ambulating subjects prior to the trauma.

          7. Subjects admitted to Emergency Room (ER) more than 24 hours (&gt; 24h) post injury.

          8. Subjects with bone fracture due to known medical history of metabolic bone diseases.

          9. Subjects with hypersensitivity to doxycycline and or tetracycline family of drugs.

         10. Subjects treated with systemic doxycycline during the last 4 weeks prior to
             screening.

         11. Previous surgical intervention in the target fracture site.

         12. Subjects currently receiving or have received an investigational product in the last
             30 days and/or participate in another clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rafael Weisz</last_name>
    <phone>+972-74-719-5700</phone>
    <phone_ext>193</phone_ext>
    <email>rafael.s@polypid.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olga Belotserkovsky</last_name>
    <phone>+972-74-719-5700</phone>
    <phone_ext>138</phone_ext>
    <email>olga.b@polypid.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah Tiqva</city>
        <state>Merkaz</state>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eliezer Sidon, Dr</last_name>
      <phone>+972-50-8464317</phone>
      <email>eli.sidon@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva`</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asaf Aker, Dr.</last_name>
      <email>aker@bgu.ac.il</email>
    </contact>
    <contact_backup>
      <last_name>Layalee Abu Naser, Dr.</last_name>
      <phone>+972-50-7314964</phone>
      <email>LayaleeAb@clalit.org.il</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alina Rubinshtein</last_name>
      <phone>972-47772932</phone>
      <email>alina.rubinshtein@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meir Liebergall, Prof.</last_name>
      <phone>+972-2-6776342</phone>
      <email>liebergall@hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Dolkart, PhD</last_name>
      <phone>:+972-524-262544</phone>
      <email>olegd@tlvmc.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>5262100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orit Yoker</last_name>
      <phone>+972-3-5302417</phone>
      <email>sheba.ortho@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>De La Salle HSI</name>
      <address>
        <city>Cavite</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Ronquillo, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippines General Hospital</name>
      <address>
        <city>Manila City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Lai, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philippine Orthopedic Center</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>December 6, 2016</lastchanged_date>
  <firstreceived_date>July 2, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Tibial Fractures</mesh_term>
    <mesh_term>Fractures, Open</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
